Each patients cancer is like fingerprint: where are we in molecular profiling in breast cancer diagnosis?

Yıl 2014, Cilt: 1 Sayı: 1, 2 - 8, 01.03.2014

Burcak Karaca Harika Atmaca Emir Bozkurt Ruchan Uslu

https://izlik.org/JA24DP49EJ

Öz

Breast cancer is the leading cause of cancer related deaths in women. Since every patient has unique molecular profile of tumorigenesis, efficient treatment choice should be tailored according to each patients gene expression profile. Therefore, it is critical to investigate molecular patterns of each patient before choosing the right treatment. For this aim, many commercial breast cancer subtyping methods are available. This review focuses on new developments and methods in molecular profiling of breast cancer.

Anahtar Kelimeler

Molecular profiling , Breast cancer , Tailored therapy

Each patient’s cancer is like fingerprint: where are we in molecular profiling in breast cancer diagnosis?

https://izlik.org/JA24DP49EJ

Öz

Kaynakça

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61(2):69-90.
• Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer research. 2001;61(16):5979-84.
• Bertucci F, Borie N, Ginestier C, Groulet A, Charafe-Jauffret E, Adelaide J, et al. Identification and validation of an ERBB2 gene expression signature 2004;23(14):2564-75. cancers. Oncogene.
• Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004;10(20):6789-95.
• Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human 2000;406(6797):747-52. tumours. Nature.
• West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(20):11462-7.
• van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-6.
• Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(19):10869-74.
• Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(14):8418-23.
• Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(18):10393-8.
• Yu K, Lee CH, Tan PH, Tan P. Conservation of breast cancer transcriptional patterns of tumor progression across distinct ethnic populations. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004;10(16):5508-17. and
• Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC genomics. 2006;7:127.
• Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative research : an official journal of the American Association 2005;11(16):5678-85. Clinical cancer for Cancer Research.
• Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004;10(16):5367-74.
• Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, et al. Gene expression characterization of triple-negative/basal-like breast carcinomas. Breast cancer research : BCR. 2007;9(5):R65. histopathological
• Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, et al. Gene-expression profiles in hereditary breast cancer. The New England journal of medicine. 2001;344(8):539-48.
• Hedenfalk I, Ringner M, Ben-Dor A, Yakhini Z, Chen Y, Chebil G, et al. Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(5):2532- 7.
• Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. Journal of the National Cancer Institute. 2003;95(19):1482-5.
• Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Begin LR, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular- proliferation+) phenotype of BRCA1-related breast cancer. Cancer research. 2004;64(3):830-5.
• Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. Journal of the National Cancer Institute. 2006;98(17):1183-92.
• Prat A, Ellis MJ, Perou CM. Practical implications of gene-expression-based assays for breast oncologists. Nature reviews Clinical oncology. 2012;9(1):48-57.
• Klein ME, Dabbs DJ, Shuai Y, Brufsky AM, Jankowitz R, Puhalla SL, et al. Prediction of the Oncotype DX recurrence score: use of pathology- generated equations derived by linear regression analysis. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2013;26(5):658-64.
• Wang Z, Dahiya S, Provencher H, Muir B, Carney E, Coser K, et al. The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007;13(21):6327-34.
• Garber K. Genomic medicine. Gene expression tests foretell breast cancer's future. Science. 2004;303(5665):1754-5.
• Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary 2005;365(9460):671-9. cancer. Lancet.
• Foekens JA, Atkins D, Zhang Y, Sweep FC, Harbeck N, Paradiso A, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(11):1665-71.
• Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. The New 2007;356(3):217-26. of medicine.
• Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, Nelson E, et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast cancer research : BCR. 2006;8(2):R23.
• Arango BA, Rivera CL, Gluck S. Gene expression profiling in breast cancer. American journal of translational research. 2013;5(2):132-8.
• Ahr A, Karn T, Solbach C, Seiter T, Strebhardt K, Holtrich U, et al. Identification of high risk breast- cancer patients by gene expression profiling. Lancet. 2002;359(9301):131-2.
• van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. The New England journal of medicine. 2002;347(25):1999-2009.
• Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. Journal of the National Cancer Institute. 2006;98(4):262-72.
• Copyright © 2014 The Author(s); This is an open-access article distributed under the terms of the Creative Commons Attribution
• License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
• provided the original work is properly cited.